Han J, Lee JD, Bibbs L, Ulevitch RJ (August 1994). “A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells”. Science265 (5173): 808–11. doi:10.1126/science.7914033. PMID7914033.
Tudor C, Marchese FP, Hitti E, Aubareda A, Rawlinson L, Gaestel M, Blackshear PJ, Clark AR, Saklatvala J, Dean JL (June 2009). “The p38 MAPK pathway inhibits tristetraprolin-directed decay of interleukin-10 and pro-inflammatory mediator mRNAs in murine macrophages”. FEBS Lett.583 (12): 1933–8. doi:10.1016/j.febslet.2009.04.039. PMID19416727.
Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR (December 2008). “Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity”. J. Pharmacol. Exp. Ther.327 (3): 610–9. doi:10.1124/jpet.108.139006. PMID18776065.
Goldstein DM, Gabriel T (2005). “Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development”. Current topics in medicinal chemistry5 (10): 1017–29. doi:10.2174/1568026054985939. PMID16178744.
nih.gov
pubmed.ncbi.nlm.nih.gov
Han J, Lee JD, Bibbs L, Ulevitch RJ (August 1994). “A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells”. Science265 (5173): 808–11. doi:10.1126/science.7914033. PMID7914033.
Tudor C, Marchese FP, Hitti E, Aubareda A, Rawlinson L, Gaestel M, Blackshear PJ, Clark AR, Saklatvala J, Dean JL (June 2009). “The p38 MAPK pathway inhibits tristetraprolin-directed decay of interleukin-10 and pro-inflammatory mediator mRNAs in murine macrophages”. FEBS Lett.583 (12): 1933–8. doi:10.1016/j.febslet.2009.04.039. PMID19416727.
Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR (December 2008). “Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity”. J. Pharmacol. Exp. Ther.327 (3): 610–9. doi:10.1124/jpet.108.139006. PMID18776065.
Goldstein DM, Gabriel T (2005). “Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development”. Current topics in medicinal chemistry5 (10): 1017–29. doi:10.2174/1568026054985939. PMID16178744.